Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers
NCT05884320Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2023
- Primary completion
- Jul 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sacituzumab govitecan in salivary gland cancer (SGC) (2 cohorts), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of Adverse Events. Started Jul 2023; status: active, not recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on NCT05884320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05884320.